Current Stem Cell Research & Therapy
ISSN 1574-888x · Bentham Science Publishers · United Arab Emirates · active 2006–2026
Flagged for closer checking
Publisher listed on Beall's archive (frozen 2017). Cross-check with DOAJ and Think.Check.Submit before submission.
This is a screening signal, not a verdict. How this check works.
Metrics
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric. Citation rates differ enormously between fields, so compare within a discipline.
Is this the right journal for your paper?
The AI Journal Finder ranks the best-matched journals for your paper’s topic — with tier, open access, citation rate and predatory flags. Free to start.
Indexing & access
Access status: unknown. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is Current Stem Cell Research & Therapy a predatory journal?
Our screening flags Current Stem Cell Research & Therapy as a possible predatory venue because its publisher appears on Beall's archive, which has been frozen since 2017. Treat this as a prompt to check carefully, not a verdict: verify against DOAJ and Think. Check. Submit before submitting.
Is Current Stem Cell Research & Therapy indexed in Scopus or Web of Science?
Per our venue index, Current Stem Cell Research & Therapy appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is the impact factor of Current Stem Cell Research & Therapy?
Papers in Current Stem Cell Research & Therapy are cited about 1.3 times each within two years of publication, and Scimago places it in Q2, with an h-index of 71. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.
What Scimago quartile is Current Stem Cell Research & Therapy (Q1, Q2, Q3, or Q4)?
Scimago places Current Stem Cell Research & Therapy in Q2 for its subject category. Quartiles split the journals in a field into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Current Stem Cell Research & Therapy is cited about 1.3 times per paper over two years, with an h-index of 71. A journal is ranked per subject category, so one spanning several fields can sit in different quartiles depending on the category.
What is the Web of Science (JCR) quartile of Current Stem Cell Research & Therapy?
The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Current Stem Cell Research & Therapy. The open equivalent is its Scimago quartile, Q2, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.
Is Current Stem Cell Research & Therapy open access?
We hold no reliable open-access classification for Current Stem Cell Research & Therapy. Check the journal's own site for its access model and any article processing charge.